Adverse karyotype amplifies risk in secondary acute myeloid leukemia (AML) and AML with myelodysplasia-related changes
sAML/AML-MRC with an adverse karyotype had a dismal outcome. These findings provide a benchmark for risk stratification in the pre- CPX-351 era.
Authors
- Shota Yoshida (ORCID: https://orcid.org/0009-0004-9998-7147)
- Shuichi Ota
- Toshihiro Matsukawa (ORCID: https://orcid.org/0000-0003-2371-3778)
- Kentaro Wakasa
- Jun Nagai
- Tatsuo Oyake (ORCID: https://orcid.org/0000-0002-8457-2211)
- Yutaka Tsutsumi (ORCID: https://orcid.org/0000-0002-4136-9678)
- Tetsuya Igarashi (ORCID: https://orcid.org/0000-0003-2486-0761)
- Makoto Ibata
- Toshiaki Hayashi (ORCID: https://orcid.org/0000-0002-9606-2542)
- T Saga
- Fumiaki Fujii
- Satoshi Iyama
- Masaaki Adachi
- Akio Mori
- Yasutaka Kakinoki
- Tomoki Takahashi
- Daigo Hashimoto
- Masahiro Onozawa
- Junichi Hashiguchi
- Katsuya Fujimoto
- Masahiro Yoshida
- Takuto Miyagishima
- Takanori Teshima
- Satoshi Yamamoto
Institutions
- Iwate Medical University (JP)
- Muroran Institute of Technology (JP)
- Sapporo Higashi Tokushukai Hospital (JP)
- Red Cross Hospital (GR)
- Kin-ikyo Chuo Hospital (JP)
- Asahikawa City Hospital (JP)
- Kushiro Rosai Hospital (JP)
- Sapporo Hokuyu Hospital (JP)
- Obihiro Kosei General Hospital (JP)
- Tenshi Hospital (JP)
- Sapporo Kosei General Hospital (JP)
- Sapporo Medical University Hospital (JP)
- Teine Keijinkai Hospital (JP)
- Sapporo City General Hospital (JP)
- Hakodate National Hospital (JP)
- Graduate School USA (US)
Publication Details
- Journal
- Hematology
- Published
- 2026-02-10
- DOI
- https://doi.org/10.1080/16078454.2026.2628479
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00